English
Russian
New prospects for urolithiasis metaphylaxis in Russia. Advisory board resolution (October 30, 2024) DOI: 10.29188/2222-8543-2025-18-1-140-144
- Martov A.G. – Dr. Sci., professor, Corresponding Member of the RAS, Head of the Department of Urology and Andrology of the A.I. Burnazyan Federal Medical and Biological Center of the Federal Medical and Biological Agency of Russia, Head of the Urology Center of the Central Clinical Hospital of Civil Aviation; Moscow, Russia; RSCI Author ID: 788667, https://orcid.org/0000-0001-6324-6110
- Prosyannikov M.Yu. – Dr. Sci., head of the department of N. Lopatkin Scientific Research Institute of urology and Interventional Radiology – branch of the National Medical Research Centre of Radiology of Ministry of health of Russian Federation; Moscow, Russia; RSCI Author ID 791050, https://orcid.org/0000-0003-3635-5244
- Saenko V.S. – Dr. Sci., Associate Professor, Professor of the Institute of Urology and Human Reproductive Health, Sechenov University; Moscow, Russia; RSCI Author ID 657575, https://orcid.org/0000-0003-3107-8161
- Malkhasyan V.A. – Dr. Sci., professor of the Department of Urology, Russian University of Medicine, Ministry of Healthcare of the Russian Federation, Head of the Urology Department, S.P. Botkin Medical Research Center; Moscow, Russia; RSCI AuthorID 943857, https://orcid.org/0000-0002-2993-884X
- Kharchilava R.R. – PhD, Director of the Training Center for Medical Practice «Praxi Medica» of the Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov of the Ministry of Health of the Russian Federation (Sechenov University); Moscow, Russia; RSCI Author ID 651346; https://orcid.org/0009-0001-6149-6041
559 Advisory board was held in Moscow оn October 30, 2024, dedicated to the problem of preventing relapses (metaphylaxis) of urolithiasis. The next questions were discussed during the meeting: the cost-effectiveness of urolithiasis metaphylaxis in the Russian Federation, what kind of patients and in what cases it is indicated, what parameters should be used to select a remedy for urolithiasis metaphylaxis. A discussion was held on the prospects for introducing metaphylaxis into urological practice in connection with the release of updated clinical guidelines for urolithiasis by the Ministry of Health of the Russian Federation, in particular, a new section on anti-relapse therapy for the disease. This section includes components of the Lit-Control® Litura® line of products that have a scientific basis and high potential in urolithiasis metaphylaxis. This line of products can be recommended for long-term use by patients with urolithiasis, from 3 months or more, with the selection of a product depending on the chemical composition of the stone and metabolic disorders, including urine acidity.
| Attachment | Size |
|---|---|
| Download | 439.79 KB |
Other issue articles
